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Background: Very little published research has actually explored the patients' knowledge about and 
willingness to participate in clinical trials and the majority of information is available from cancer 
studies. 
Objectives: We aimed to explore the rheumatology patients' knowledge about clinical trials with a 
view to improving their involvement in our departmental research projects. 
Methods: We conducted a questionnaire-based study, comprising 2 opinion questions about clinical 
trials knowledge and willingness to take part in research; 18 knowledge questions about the clinical 
research principles and 4 questions about what could improve patients' understanding and 
participation in clinical research. The questionnaire was adapted from a recent cancer patients' 
study (1). Correlation coefficients above 0.6 were considered as strong, as per the accepted cut-off 
for social science studies. 
Results: 85 patients fully completed the questionnaire during their appointments in our 
rheumatology clinics (63 females, 22 males, mean age 50.9±16.2 years); 25 patients (29.4%) were 
seen as new patients, and 60 (70.5%) are under regular follow-up for the management of 
rheumatoid arthritis (45.8%), osteoporosis (24.7%), osteoarthritis (14.1%) and other conditions 
(median duration of follow-up was 3±0.74 years). Under a quarter (21.1%) of patients had previously 
participated in clinical research, but 45% of patients considered that they had good understanding 
about clinical trials, 27% were neutral about this statement and 28% disagreed. The good 
understanding correlated well with patients' history of participation in research (r=0.62, p<0.05). 
Only 12.9% wished to participate in future in clinical trials, while 42.3% patients did not (44.7% were 
neutral). The biggest consensus was reached on the following points: a clinical trial is a test of an 
experimental drug (77.6% agreement); statistics help to decide whether an experimental treatment 
is better than the available treatments (76.5%); proving the efficacy of a drug in vitro is not enough 
to enable its use in humans (74.2%). Specific questions about definitions of placebo, standard vs. 
experimental treatment and randomisation generated a significant degree of uncertainty (52.9%, 
52.9%, and 50.5% respectively of patients replied “I don't know”). The main incentive for 
participation in research was the hope for better care and more time with the clinician (45.8%). Only 
9.4% would consider this option because of their poor disease control, but this correlated well with 
patients' previous participation in research (r=0.71; p<0.05). The lack of understanding of research 
principles correlated with the lack of willingness to participate in clinical trials (r=0.72; p<0.05) 
Conclusions: The results of our study revealed that patients lack information about clinical trials and 
have difficultly understanding the principles of medical research. The need for more clinician time 
was perceived as one of the incentives to enrol in clinical research, showing that research could 
improve our patients' experience of care. 
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